A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain

被引:0
|
作者
Li, Siman [1 ]
Wang, Binding [1 ]
Deng, Jiayao [2 ]
Li, Haiyan [2 ]
Wu, Yong [3 ]
Fang, Yu [2 ]
Yan, Bohua [2 ]
Chen, Yu [2 ]
机构
[1] Chengdu Univ TCM, Sch Clin Med, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Zhongxiang Pharmaceut Technol Co Ltd, Chengdu, Sichuan, Peoples R China
来源
JOURNAL OF PAIN RESEARCH | 2025年 / 18卷
关键词
primary liver cancer; traditional Chinese medicine; Chinese herb; cancer pain management; randomized controlled trial; MECHANISMS;
D O I
10.2147/JPR.S500305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer- related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain. The Fuzhengxiaoliu patch (FZXLP) is a compound TCM with the effects of detoxification and pain relief and has shown great efficacy in the treatment of patients with liver cancer, but high-quality clinical research that provides research-based evidence is lacking. We designed a randomized, double-blind, placebo-controlled trial to explore and evaluate the efficacy of FZXLP for the treatment of liver cancer pain. Methods: This is a prospective, randomized, double-blind, placebo-controlled trial. The trial will enrol 72 participants with primary liver cancer with cancer pain (damp-heat stagnation and toxin and blood stasis syndrome). The primary objective is to measure the reduction in pain using FZXLP in combination with tegafur, gimeracil and oteracil potassium capsule (S-1) compared to the placebo group with S-1. Pain will be measured by the number of opioids used, Chinese versions of the numerical rating scale (NRS), pain relief rate and number of breakthrough cases of cancer pain (BTcP). The secondary objectives include response evaluation criteria in solid tumors (RECIST), tumor markers, TCM syndrome scores, weight, functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire scores, and self-rating anxiety scale scores. Adverse events (AEs) will be recorded throughout the study. Discussion: This study integrated TCM with clinical research to assess the efficacy and safety of the addition of FZXLP in the treatment of primary liver cancer pain. Trial registration: Chinese clinical trial registry, ChiCTR2300076951, Registered on October 25, 2023. https://www.chictr.org.cn/ showproj.html?proj=209608.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [1] Gabapentin in the Management of Pain following Tonsillectomy: A Randomized Double-Blind Placebo-Controlled Trial
    Sanders, James G.
    Cameron, Claire
    Dawes, Patrick J. D.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 157 (05) : 781 - 790
  • [2] Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial
    Khan, AA
    Bilezikian, JP
    Kung, AWC
    Ahmed, MM
    Dubois, SJ
    Ho, AYY
    Schussheim, D
    Rubin, MR
    Shaikh, AM
    Silverberg, SJ
    Standish, TI
    Syed, Z
    Syed, ZA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3319 - 3325
  • [3] Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, Eduardo
    El Osta, Badi
    Valero, Vicente
    Driver, Larry C.
    Pei, Be-Lian
    Shen, Loren
    Poulter, Valerie A.
    Palmer, J. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3475 - 3481
  • [4] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [5] Pamidronate for pain in adult chronic nonbacterial osteitis: protocol of a randomized, double-blind, placebo-controlled trial
    Leerling, Anne T.
    Canete, Ana Navas
    Smit, Frits
    Hamdy, Neveen A. T.
    van de Burgt, Alina
    Appelman-Dijkstra, Natasha M.
    Dekkers, Olaf M.
    Winter, Elizabeth M.
    JBMR PLUS, 2024, 8 (10)
  • [6] Caffeine as an Adjuvant Therapy to Opioids in Cancer Pain: A Randomized, Double-Blind, Placebo-Controlled Trial
    Suh, Sang-Yeon
    Choi, Youn Seon
    Oh, Sang Cheul
    Kim, Young Sung
    Cho, Kyunghee
    Bae, Woo Kyung
    Lee, Ju Hyun
    Seo, Ah-ram
    Ahn, Hong-Yup
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 46 (04) : 474 - 482
  • [7] Intraoperative acupuncture for posttonsillectomy pain: A randomized, double-blind, placebo-controlled trial
    Tsao, Gabriel J.
    Messner, Anna H.
    Seybold, Jeannie
    Sayyid, Zahra N.
    Cheng, Alan G.
    Golianu, Brenda
    LARYNGOSCOPE, 2015, 125 (08): : 1972 - 1978
  • [8] A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain
    Wallace, MS
    Rowbotham, MC
    Katz, NP
    Dworkin, RH
    Dotson, RM
    Galer, BS
    Rauck, RL
    Backonja, MM
    Quessy, SN
    Meisner, PD
    NEUROLOGY, 2002, 59 (11) : 1694 - 1700
  • [9] A randomized, double-blind, placebo-controlled trial of ormeloxifene in breast pain and nodularity
    Kumar, Sandeep
    Rai, Ruchi
    Agarwal, G. G.
    Dwivedi, Varsha
    Kumar, Surender
    Das, Vinita
    NATIONAL MEDICAL JOURNAL OF INDIA, 2013, 26 (02): : 69 - 74
  • [10] Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial
    Hatami, Behzad
    Mosala, Mozhde
    Hassani, Amir Hossein
    Ardakani, Mohammad Javad Ehsani
    Gholami, Samira
    Zali, Mohammad Reza
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (04):